Which blood thinner costs less for cancer patients with clots? study investigates.
NCT ID NCT05643885
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at medical costs for cancer patients who had a blood clot (VTE) and were treated with either apixaban or low molecular weight heparin. Researchers analyzed insurance claims from over 7,300 patients to compare total healthcare costs, including hospital stays and pharmacy bills. The goal was to see which treatment might be more affordable for patients and the healthcare system.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
7,304 people
The number who actually took part.
- Started
-
Aug 2022
- Finished
-
Aug 2024
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with active cancer who are newly diagnosed with venous thromboembolism (VTE) and treated with apixaban or low molecular weight heparin within 30 days following the VTE. Patients will be identified from the PharMetrics Plus health care claims database between the period of January 2017 and October 2021 if they have a VTE diagnosis and claim for apixaban or low molecular weight heparin during this time.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Venous thromboembolism (VTE) diagnosis between January 1 2017 and October 31 2021 * Evidence of active cancer * At least 1 claim for apixaban or low molecular weight heparin (LMWH) * Age 18 years or older Exclusion Criteria: * diagnosis of atrial fibrillation/flutter * procedure for mechanical heart valve or inferior vena cava filter * VTE diagnosis in the baseline period * anticoagulant therapy in the baseline period * pregnancy
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cancer are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Investigational
New York, New York, 10017, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can colorectal surgery patients go home in two days?
- Can a personal navigator help young cancer patients through treatment?
- Can a smartwatch predict which cancer patients return to hospital?
- Ulcerative colitis drugs put under the microscope for hidden clot risk
- Two-Drug combo aims to stall advanced breast cancer
- Blood thinner flush could boost tumor biopsy success